Ryan Scott
Articles
Entrectinib Generates Favorable Outcomes in NTRK Fusion+ Breast Cancer
May 14, 2022
Article
Entrectinib elicited encouraging responses in patients with breast cancer that harbors NTRK fusions, according to updates from the phase 2 STARTRK-2 trial.
Investigational RNA Interference Therapy, ARO-HIF2, Yields Encouraging Phase 1 Results in Clear Cell RCC
May 12, 2022
Article
Patients with clear cell renal cell carcinoma experienced reduced levels of hypoxia inducible factor-2 alpha expression following treatment with ARO-HIF2.
Telemedicine Use During COVID-19 Disparate Between White and Black Patients With Hematologic Cancers
March 30, 2022
Article
The disparate use in telemedicine between White and Black patients warrants further exploration into compound cases, such as economic and societal factors.
Coordination With Ophthalmologists Ideal for Mitigating Belantamab Mafodotin–Related Vision Problems in Multiple Myeloma
March 04, 2022
Article
A proactive, multidisciplinary approach is the best way to address belantamab mafodotin—related keratopathy in patients with multiple myeloma.
Investigators Seek to Evaluate Obe-Cel’s Role in Relapsed/Refractory B-Cell ALL
March 03, 2022
Article
An expert with Moffitt Cancer Center comments on the ongoing FELIX trial, and the potential of the novel CAR T-cell therapy, obecabtagene autoleucel, to change the B-cell acute lymphoblastic leukemia treatment paradigm.
High Rate of High-Risk Endometrial Cancer in Black Women Demands Attention and Further Research Into Underlying Disparities
February 01, 2022
Article
An expert from the University of California Los Angeles (UCLA) discusses the alarming rate of high-risk uterine cancers among Black women and how researchers are investigating the underlying risk factors at play.
Potentially Game-Changing Clinical Trials in Endometrial Cancer Seek to Evaluate Immunotherapeutic Approaches
January 31, 2022
Article
An expert from the University of Colorado (UC Health) comments on ongoing clinical trials which promise to shake up the treatment paradigm of endometrial cancer.
Oral Decitabine and Cedazuridine Holds Potential to Reduce Clinic Visits, Infusion Time for Patients With Lower-Risk MDS
January 14, 2022
Article
Oral decitabine, an oral fixed-dose of combination decitabine and CDA inhibitor cedazuridine, is an FDA-approved therapy for patients with lower-risk myelodysplastic syndromes.
Ruxolitinib Remains Backbone in Myelofibrosis and MPN Treatment
January 04, 2022
Article
An expert from Mount Sinai Hospital comments on potential new ruxolitinib combinations to treat patients with myelofibrosis and MPNs.
Understanding Translocation RCC Biology, Genomic Drivers May Provide Answers Needed for Better Targeted Treatments Options
October 31, 2021
Article
An expert from Dana-Farber Cancer Institute comments on ongoing research in translocation RCC and next steps for research in this treatment space.